Myriad Genetics (MYGN): Glenview Capital and Larry Robbins report exit from stake

Rhea-AI Filing Summary

Myriad Genetics, Inc. received an updated ownership report from Glenview Capital Management, LLC and Larry Robbins. As of June 30, 2026, the reporting persons state they may be deemed the beneficial owners of 0 shares of Myriad Genetics common stock, representing 0% of the outstanding shares. The filing confirms they hold no sole or shared voting or dispositive power over any Myriad Genetics shares, indicating they no longer report a significant ownership position in the company.

Key Figures

Beneficial ownership: 0 Shares Percent of class: 0% Sole voting power: 0 Shares +3 more

6 metrics

Beneficial ownership 0 Shares Shares of Myriad Genetics common stock beneficially owned as of June 30, 2026

Percent of class 0% Percentage of Myriad Genetics common stock beneficially owned as of June 30, 2026

Sole voting power 0 Shares Shares over which reporting persons have sole voting power

Shared voting power 0 Shares Shares over which reporting persons have shared voting power

Sole dispositive power 0 Shares Shares over which reporting persons have sole dispositive power

Shared dispositive power 0 Shares Shares over which reporting persons have shared dispositive power

Key Terms

beneficial owner, Sole Voting Power, Dispositive Power, Ownership of 5 Percent or Less of a Class, +1 more

5 terms

beneficial owner financial

"each of the Reporting Persons may be deemed the beneficial owner of 0 Shares"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

Sole Voting Power financial

"5 | Sole Voting Power 0.00 6 | Shared Voting Power 0.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Dispositive Power financial

"Sole Dispositive Power 0.00 8 | Shared Dispositive Power 0.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

Ownership of 5 Percent or Less of a Class regulatory

"Item 5. | Ownership of 5 Percent or Less of a Class."

Schedule 13G regulatory

"If a parent holding company has filed this schedule, pursuant to (ii)(G)"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

FAQ

What did Glenview Capital disclose about its MYGN ownership in this Schedule 13G/A?

Glenview Capital Management and Larry Robbins disclosed that, as of June 30, 2026, they may be deemed the beneficial owners of 0 shares of Myriad Genetics (MYGN), representing 0% of the company’s outstanding common stock.

What percentage of Myriad Genetics (MYGN) does Glenview Capital currently report owning?

The reporting persons state they may be deemed to beneficially own 0% of Myriad Genetics (MYGN) common stock. They report no sole or shared voting power and no sole or shared dispositive power over any MYGN shares.

As of what date did Glenview Capital report 0% ownership of MYGN?

The ownership information is reported as of June 30, 2026. On that date, Glenview Capital Management and Larry Robbins reported beneficial ownership of 0 shares of Myriad Genetics (MYGN), corresponding to 0% of the outstanding shares.

Who are the reporting persons in this Myriad Genetics (MYGN) Schedule 13G/A filing?

The reporting persons are Glenview Capital Management, LLC and Larry Robbins. Glenview Capital Management serves as investment manager to certain funds, and Larry Robbins is its Chief Investment Officer, according to the filing.

Does Glenview retain any voting or dispositive power over Myriad Genetics (MYGN) shares?

No. The filing reports 0 shares with sole or shared voting power and 0 shares with sole or shared dispositive power. This indicates Glenview and Larry Robbins report no control over any MYGN shares as of June 30, 2026.

Which funds previously held MYGN shares associated with Glenview Capital?

The statement relates to shares held for the accounts of Glenview Capital Master Fund, Ltd., Glenview Offshore Opportunity Master Fund, Ltd., and Glenview Healthcare Master Fund, L.P., for which Glenview Capital Management acts as investment manager.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 04:59 PM Accepted by SEC EDGAR 08/14/2026 - 04:59 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

MYRIAD GENETICS INC

(Name of Issuer)

Common Stock, par value $0.01 per share

(Title of Class of Securities)

62855J104

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 62855J104

1

Names of Reporting Persons

GLENVIEW CAPITAL MANAGEMENT, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 62855J104

1

Names of Reporting Persons

ROBBINS LARRY

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

IN, HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: MYRIAD GENETICS INC
(b)	Address of issuer's principal executive offices: 322 North 2200 West, Salt Lake City, Utah, 84116
Item 2.
(a)	Name of person filing: This Statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons"): i. Glenview Capital Management, LLC ("Glenview Capital Management") ii. Larry Robbins ("Mr. Robbins"). This Statement relates to shares of Common Stock, par value $0.01 per share ("Shares") held for the accounts of Glenview Capital Master Fund, Ltd., a Cayman Islands exempted company ("Glenview Capital Master Fund"), Glenview Offshore Opportunity Master Fund, Ltd., a Cayman Islands exempted company ("Glenview Offshore Opportunity Master Fund"), and Glenview Healthcare Master Fund, L.P., a Cayman Islands limited partnership ("Glenview Healthcare Master Fund"). Glenview Capital Management serves as investment manager to each of Glenview Capital Master Fund, Glenview Offshore Opportunity Master Fund and Glenview Healthcare Master Fund. Mr. Robbins is the Chief Investment Officer of Glenview Capital Management.
(b)	Address or principal business office or, if none, residence: The address of the principal business office of each of the Reporting Persons is 520 Madison Avenue, 33rd Floor, New York, New York 10022.
(c)	Citizenship: i. Glenview Capital Management is a Delaware limited liability company ii. Mr. Robbins is a citizen of the United States of America.
(d)	Title of class of securities: Common Stock, par value $0.01 per share
(e)	CUSIP No.: 62855J104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: As of June 30, 2026, each of the Reporting Persons may be deemed the beneficial owner of 0 Shares.
(b)	Percent of class: As of June 30, 2026, each of the Reporting Persons may be deemed the beneficial owner of 0% of the Shares outstanding.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See disclosure in Items 2 and 4 hereof. Certain funds listed in Item 2(a) are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares covered by this Statement that may be deemed to be beneficially owned by the Reporting Persons.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See disclosure in Item 2 hereof.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

GLENVIEW CAPITAL MANAGEMENT, LLC

Signature:	/s/ Mark J. Horowitz
Name/Title:	Mark J. Horowitz, President
Date:	08/14/2026

ROBBINS LARRY

Signature:	/s/ Mark J. Horowitz
Name/Title:	Mark J. Horowitz, attorney-in-fact for Larry Robbins
Date:	08/14/2026

Exhibit Information

Exhibit 1: Joint Filing Agreement Exhibit 2: Power of Attorney